Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit

  • Melvin J. Rivera
  • Bryan Do
  • Jeffrey C. Bryan
  • Terri Lynn Shigle
  • Rina PatelEmail author
Reference work entry


Advances in the management of hematologic malignancies and solid tumors have given rise to diverse modalities to treat cancer other than cytotoxic chemotherapy, including targeted therapies, immunotherapies, and cellular therapies. Currently, there are over 175 FDA-approved antineoplastic agents in the United States, many with a diverse and profound toxicity profile. Complications of antineoplastic therapy may result in the need for intensive care unit (ICU) admission to provide acute symptom management. Accordingly, ICU providers caring for cancer patients should have a working knowledge of the toxicities and complications associated with antineoplastic therapy.


Chemotherapy Immunotherapy Cancer Toxicity Oncology Critical care Intensive care Complications Adverse effects Antineoplastic agents 


  1. 1.
    Abraxis Bioscience LLC. Abraxane (paclitaxel protein-bound particles) [package insert]. Summit; 2017.Google Scholar
  2. 2.
    Accord Healthcare Inc. Toposar (etoposide) [package insert]. Durham; 2014.Google Scholar
  3. 3.
    Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128(15):1940–3. Scholar
  4. 4.
    Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, Valent P. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533–9. Scholar
  5. 5.
    Aldoss I, Douer D, Behrendt CE, Chaudhary P, Mohrbacher A, Vrona J, Pullarkat V. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016;96(4):375–80. Scholar
  6. 6.
    Allos Therapeutics. Folotyn (pralatrexate) [package insert]. Westminister; 2009.Google Scholar
  7. 7.
    Amgen. Blincyto® (Blinatumomab) [package insert]. Thousand Oaks; 2017a.Google Scholar
  8. 8.
    Amgen. Vectibix (panitumumab) [package insert]. Thousand Oaks; 2017b.Google Scholar
  9. 9.
    Ariad Pharmaceuticals Inc. Alunbrig (brigatinib) [package insert]. Cambridge, MA; 2017.Google Scholar
  10. 10.
    Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol. 2017;28(12):2932–42. Scholar
  11. 11.
    Asbury RF, Rosenthal SN, Descalzi ME, Ratcliffe RL, Arseneau JC. Hepatic veno-occlusive disease due to DTIC. Cancer. 1980;45(10):2670–4.CrossRefGoogle Scholar
  12. 12.
    AstraZeneca. Imfinzi (durvalumab) [package insert]. Wilmington; 2016.Google Scholar
  13. 13.
    AstraZeneca Pharmaceuticals. Calquence (acalabrutinib) [package insert]. Wilmington; 2017a.Google Scholar
  14. 14.
    AstraZeneca Pharmaceuticals. Lynparza (olaparib) capsules [package insert]. Wilmington; 2017b.Google Scholar
  15. 15.
    Au TH, Cavalieri CC, Stenehjem DD. Ceritinib: a primer for pharmacists. J Oncol Pharm Pract. 2017;23(8):602–14. Scholar
  16. 16.
    Azambuja E, Fleck JF, Batista RG, Menna Barreto SS. Bleomycin lung toxicity: who are the patients with increased risk? Pulm Pharmacol Ther. 2005;18(5):363–6. Scholar
  17. 17.
    AztraZeneca Pharmaceuticals LP. Iressa (gefitinib) [package insert]. Wilmington; 2015.Google Scholar
  18. 18.
    AztraZeneca Pharmaceuticals LP. Tagrisso (osimertinib) [package insert]. Wilmington; 2017.Google Scholar
  19. 19.
    Baker WJ, Royer GL Jr, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol. 1991;9(4):679–93. Scholar
  20. 20.
    Baron M, Zini JM, Challan Belval T, Vignon M, Denis B, Alanio A, Malphettes M. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Leuk Lymphoma. 2017;58(12):2981–2. Scholar
  21. 21.
    Baxter. Cyclophosphamide Injection [package insert]. Deerfield; 2015.Google Scholar
  22. 22.
    Baxter Healthcare Corp. Ifex (ifosfamide) [prescribing information]. Deerfield; 2014.Google Scholar
  23. 23.
    Bayer Healthcare Pharmaceuticals Inc. Aliqopa (copanlisib) [package insert]. Whippany; 2017a.Google Scholar
  24. 24.
    Bayer Healthcare Pharmaceuticals Inc. Nexevar (sorafenib) [package insert]. Whippany; 2017b.Google Scholar
  25. 25.
    Bayer HealthCare Pharmaceuticals Inc. Stivarga (regorafenib) [package insert]. Whippany; 2017c.Google Scholar
  26. 26.
    Bedford Laboratories. Adriamycin (doxorubicin HCL) [package insert]. Bedford; 2012.Google Scholar
  27. 27.
    Bedford Laboratories. Daunorubicin hydrochloride injection [package insert]. Bedford; 2013.Google Scholar
  28. 28.
    Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, Bruzzoni-Giovanelli H, Calvo F, Tazi A, Rousselot P. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007;176(8):814–8. Scholar
  29. 29.
    Bielopolski D, Evron E, Moreh-Rahav O, Landes M, Stemmer SM, Salamon F. Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature. J chemother (Florence, Italy). 2017;29(2):113–7. Scholar
  30. 30.
    Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011;17(18):5858–66. Scholar
  31. 31.
    Boehringer-ingelheim. Gilotrif (afatinib) [package insert]. Ridgfield; 2018.Google Scholar
  32. 32.
    Bohra C, Sokol L, Dalia S. Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review. Cancer Control. 2017;24(4):1073274817729901. Scholar
  33. 33.
    Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018a;36:1714–68. Scholar
  34. 34.
    Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018b;36:1714–68. (Published online: February 14, 2018).CrossRefGoogle Scholar
  35. 35.
    Bristol-Myers Squibb. Ixempra (ixabepilone) [package insert]. Princeton; 2007.Google Scholar
  36. 36.
    Bristol-Myers Squibb. Opdivo (nivolumab) [package insert]. Princeton; 2018.Google Scholar
  37. 37.
    Bristol-Myers Squibb Company. Blenoxane (bleomycin) [package insert]. Princeton; 2010a.Google Scholar
  38. 38.
    Bristol-Myers Squibb Company. Platinol (cisplatin) [package insert]. Princeton; 2010b.Google Scholar
  39. 39.
    Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. Princeton; 2017a.Google Scholar
  40. 40.
    Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. Princeton; 2017b.Google Scholar
  41. 41.
    Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374(4):323–32. Scholar
  42. 42.
    Camacho LH. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med. 2015;4(5):661–72. Scholar
  43. 43.
    Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478–84. Scholar
  44. 44.
    Canzler U, Schmidt-Gohrich UK, Bergmann S, Hanseroth K, Gatzweiler A, Distler W. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by vinorelbine treatment of metastatic breast cancer. Onkologie. 2007;30(8–9):455–6. Scholar
  45. 45.
    Carilli A, Favis G, Sundharkrishnan L, Hajdenberg J. Severe dermatologic reactions with bendamustine: a case series. Case Rep Oncol. 2014;7(2):465–70. Scholar
  46. 46.
    Carron PL, Cousin L, Caps T, Belle E, Pernet D, Neidhardt A, Capellier G. Gemcitabine-associated diffuse alveolar hemorrhage. Intensive Care Med. 2001;27(9):1554. Scholar
  47. 47.
    Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834–40. Scholar
  48. 48.
    Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, Moskowitz AJ, Rook AH, Jalan P, Loren AW, Landsburg D, Coyne T, Tsai D, Raisch DW, Norris LB, Bookstaver PB, Sartor O, Bennett CL. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014;120(16):2464–71. Scholar
  49. 49.
    Celegene Corporation. Pomalyst (pomalidomide) [package insert]. Summit; 2018.Google Scholar
  50. 50.
    Celgene Corporation. 2016 Istodax (romidepsin) [package insert]. Summit; 2018.Google Scholar
  51. 51.
    Celgene Corporation. Thalomid (thalidomide) [package insert]. Summit; 2017.Google Scholar
  52. 52.
    Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(5):523–36. Scholar
  53. 53.
    Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075–88. Scholar
  54. 54.
    Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–96. Scholar
  55. 55.
    Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40. Scholar
  56. 56.
    Costa R, Costa R, Costa R, Junior GM, Cartaxo HQ, de Barros AC. Reversible posterior encephalopathy syndrome secondary to sunitinib. Case Rep Oncol Med. 2014;2014:952624. Scholar
  57. 57.
    Cowman S, Stebbing J, Tuthill M. Large bowel perforation associated with capecitabine treatment for breast cancer. Ann Oncol. 2008;19(8):1510–1. Scholar
  58. 58.
    Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22(3):400–9. Scholar
  59. 59.
    De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, Gardembas M, Stamatoulas A, Conde E, Guerci A, Gardin C, Geiser K, Makhoul DC, Reman O, de la Serna J, Lefrere F, Chomienne C, Chastang C, Degos L, Fenaux P. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998;92(8):2712–8.PubMedGoogle Scholar
  60. 60.
    de Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, Canal P, Chevreau C, Carrie D, Soulie P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 1992;10(11):1795–801. Scholar
  61. 61.
    Dendreon Corporation. Provenge (sipuleucel-T) [package insert]. Seattle; 2014.Google Scholar
  62. 62.
    Dhesi S, Chu MP, Blevins G, Paterson I, Larratt L, Oudit GY, Kim DH. Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management. J Invest Med High Impact Case Rep. 2013;1(1):2324709613480346. Scholar
  63. 63.
    Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Ziogas D, Eleutherakis-Papaiakovou E, Fotiou D, Migkou M, Kanellias N, Panagiotidis I, Ntalianis A, Papadopoulou E, Stamatelopoulos K, Manios E, Pamboukas C, Kontogiannis S, Terpos E, Kastritis E. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017;1(7):449–54. Scholar
  64. 64.
    Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Loman N, Robertson JD, Mann H, Kaufman B. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140(2):199–203. Scholar
  65. 65.
    Douer D, Aldoss I, Lunning MA, Burke PW, Ramezani L, Mark L, Vrona J, Park JH, Tallman MS, Avramis VI, Pullarkat V, Mohrbacher AM. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol. 2014;32(9):905–11. Scholar
  66. 66.
    Dutcher JP, Schwartzentruber DJ, Kaufman HL, Agarwala SS, Tarhini AA, Lowder JN, Atkins MB. High dose interleukin-2 (Aldesleukin) – expert consensus on best management practices-2014. J Immuno Ther Cancer. 2014;2(1):26. Scholar
  67. 67.
    Eisai Inc. Lenvima (lenvatinib) capsules [package insert]. Woodcliff Lake; 2017.Google Scholar
  68. 68.
    Eli Lilly and Company. Portrazza (necitumumab) [package insert]. Indianapolis; 2015.Google Scholar
  69. 69.
    Eli Lilly and Company. Erbitux (cetuximab) [package insert]. Indianapolis; 2016Google Scholar
  70. 70.
    Eli Lilly and Company. Alimta (pemetrexed) [package insert]. Indianapolis; 2017a.Google Scholar
  71. 71.
    Eli Lilly and Company. Cyramza (ramucirumab) [package insert]. Indianapolis; 2017bGoogle Scholar
  72. 72.
    Eli Lilly and Company. Gemzar (gemcitabine) [package insert]. Indianapolis; 2017c.Google Scholar
  73. 73.
    EMD Serono. Bavencio (avelumab) [package insert]. Rockland; 2017.Google Scholar
  74. 74.
    EMD Serono. Novantrone (Mitoxantrone) [package insert]. Rockland; 2008.Google Scholar
  75. 75.
    Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129–36. Scholar
  76. 76.
    Exelixis Inc. Cometriq (cabozantinib) [package insert]. South San Francisco; 2017.Google Scholar
  77. 77.
    Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008;112(5):1638–45. Scholar
  78. 78.
    Feinberg WM, Swenson MR. Cerebrovascular complications of L-asparaginase therapy. Neurology. 1988;38(1):127–33.CrossRefGoogle Scholar
  79. 79.
    Gass-Jegu F, Gschwend A, Gairard-Dory AC, Mennecier B, Tebacher-Alt M, Gourieux B, Quoix E. Gastrointestinal perforations in patients treated with erlotinib: a report of two cases with fatal outcome and literature review. Lung Cancer (Amsterdam, Netherlands). 2016;99:76–8. Scholar
  80. 80.
    Geiser CF, Bishop Y, Jaffe N, Furman L, Traggis D, Frei E 3rd. Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood. 1975;45(2):189–95.PubMedGoogle Scholar
  81. 81.
    Genentech Inc. Herceptin (trastuzumab) [package insert]. South San Francisco; 2017a.Google Scholar
  82. 82.
    Genentech Inc. Kadcyla (ado-traztuzumab emtansine) [package insert]. South San Francisco; 2017b.Google Scholar
  83. 83.
    Genentech Inc. Perjeta (pertuzumab) [package insert]. South San Francisco; 2017c.Google Scholar
  84. 84.
    Genentech Inc. Cotellic (cobimetinib) [package insert]. South San Francisco; 2018.Google Scholar
  85. 85.
    Genentech USA Inc. Xeloda (capecitabine) [package insert]. South San Francisco; 2016Google Scholar
  86. 86.
    Genentech USA Inc. Alecensa (alectinib) [package insert] South San Francisco; 2017a.Google Scholar
  87. 87.
    Genentech USA Inc. Avastin (bevacizumab) [package insert]. South San Francisco; 2017b.Google Scholar
  88. 88.
    Genentech USA Inc. Erivedge (vismodegib) [package insert]. South San Francisco; 2017c.Google Scholar
  89. 89.
    Genentech USA Inc. Tecentriq (atezolizumab) [package insert]. South San Francisco; 2017d.Google Scholar
  90. 90.
    Genentech USA Inc. Zelboraf (vemurafenib) [package insert]. South San Francisco; 2017e.Google Scholar
  91. 91.
    Genzyme Corporation. Lemtrada (alemtuzumab) [package insert]. Cambridge, MA; 2017.Google Scholar
  92. 92.
    Geyer HL, Viggiano RW, Lacy MQ, Witzig TE, Leslie KO, Mikhael JR, Stewart K. Acute lung toxicity related to pomalidomide. Chest. 2011;140(2):529–33. Scholar
  93. 93.
    Gilead Sciences. Zydelig (idelalisib) [package insert]. Foster City; 2016.Google Scholar
  94. 94.
    Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, Hochhaus A, le Coutre PD, Saglio G. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27(6):1310–5. Scholar
  95. 95.
    GlaxoSmithKline. Alkeran®(melphalan) [package insert]. Research Triangle Park; 2012.Google Scholar
  96. 96.
    Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Pal RS, Brezden-Masley C, Gavura S, Lien K, Chan KK. The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study. J Natl Cancer Inst. 2016;108(1).
  97. 97.
    Grellety T, Houede N, Hoepffner JL, Riviere J, Merino C, Lieutenant V, Gross-Goupil M, Richaud P, Dupin C, Sargos P, Roubaud G. Hemorrhagic cystitis in patients treated with cabazitaxel: a radiation recall syndrome? Ann Oncol. 2014;25(6):1248–9. Scholar
  98. 98.
    Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst. 2011;103(21):1572–87. Scholar
  99. 99.
    Haskell CM, Canellos GP, Leventhal BG, Carbone PP, Block JB, Serpick AA, Selawry OS. l-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med. 1969;281(19):1028–34. Scholar
  100. 100.
    Helman DL Jr, Byrd JC, Ales NC, Shorr AF. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest. 2002;122(3):785–90.CrossRefGoogle Scholar
  101. 101.
    Heritage Pharmaceuticals. BiCNU (carmustine) [package insert]. Eatontown; 2017.Google Scholar
  102. 102.
    Herzig RH, Hines JD, Herzig GP, Wolff SN, Cassileth PA, Lazarus HM, Adelstein DJ, Brown RA, Coccia PF, Strandjord S, et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol. 1987;5(6):927–32. Scholar
  103. 103.
    Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–54. Scholar
  104. 104.
    Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andre F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O’Shaughnessy J. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48. Scholar
  105. 105.
    Hospira. Nipent (pentostatin for injection) [package insert]. Lake Forest; 2018.Google Scholar
  106. 106.
    Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, Sabichi AL, Wong SL, Artz AS. Hepatitis B virus screening for patients with cancer before therapy: American society of clinical oncology provisional clinical opinion update. J Clin Oncol. 2015;33(19):2212–20. Scholar
  107. 107.
    Ikeda S, Sekine A, Kato T, Yoshida M, Ogata R, Baba T, Nagahama K, Okudela K, Ogura T. Diffuse alveolar hemorrhage as a fatal adverse effect of bevacizumab: an autopsy case. Jpn J Clin Oncol. 2014;44(5):497–500. Scholar
  108. 108.
    Incyte Corp. Jakafi (ruxolitinib) [package insert]. Wilmington; 2011.Google Scholar
  109. 109.
    Ingenus Pharmaceuticals. Carboplatin [package insert]. Orlando; 2017.Google Scholar
  110. 110.
    Jain S, Song R, Xie J. Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas. Onco Targets Ther. 2017;10:1645–53. Scholar
  111. 111.
    Janssen Biotech. Darzalex (daratumumab) [package insert]. Horsham; 2017.Google Scholar
  112. 112.
    Janssen Products. Yondelis (trabectedin) [package insert]. Horsham; 2015.Google Scholar
  113. 113.
    Janssen Products. Doxil (doxorubicin HCl liposome injection) [package insert]. Horsahm; 2016.Google Scholar
  114. 114.
    Jazz Pharmaceuticals. VYXEOS (daunorubicin and cytarabine) liposome [package insert]. Palo Alto; 2018.Google Scholar
  115. 115.
    Jazz Pharmaceuticals. Erwinaze intramuscular injection, intravenous injection (asparaginase Erwinia chrysanthemi intramuscular injection, intravenous injection) [package insert]. Palo Alto; 2016.Google Scholar
  116. 116.
    Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–55. Scholar
  117. 117.
    Johnston PB, Bondly C, Micallef IN. Ibritumomab tiuxetan for non-Hodgkin’s lymphoma. Expert Rev Anticancer Ther. 2006;6(6):861–9. Scholar
  118. 118.
    Jolson HM, Bosco L, Bufton MG, Gerstman BB, Rinsler SS, Williams E, Flynn B, Simmons WD, Stadel BV, Faich GA, et al. Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine. J Natl Cancer Inst. 1992;84(7):500–5.CrossRefGoogle Scholar
  119. 119.
    June Therapeutics. Juno Therapeutics and Celgene corporation release additional data from TRANSCEND trial of JCAR017 in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. 2017, viewed 11 March 2018.
  120. 120.
    Junpaparp P, Sharma B, Samiappan A, Rhee JH, Young KR. Everolimus-induced severe pulmonary toxicity with diffuse alveolar hemorrhage. Ann Am Thorac Soc. 2013;10(6):727–9. Scholar
  121. 121.
    Kadia TM, Gandhi V. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert Rev Hematol. 2017;10(1):1–8. Scholar
  122. 122.
    Kanie K, Iguchi G, Bando H, Fujita Y, Odake Y, Yoshida K, Matsumoto R, Fukuoka H, Ogawa W, Takahashi Y. Two cases of atezolizumab-induced hypophysitis. J Endocr Soc. 2018;2(1):91–5. Scholar
  123. 123.
    Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, Ejduk AA, O’Brien SM, Jabbour EJ, Zhang H, Sleight BJ, Vandendries ER, Marks DI. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4(8):e387–98. Scholar
  124. 124.
    Kebriaei P, Wilhelm K, Ravandi F, Brandt M, de Lima M, Ciurea S, Worth L, O'Brien S, Thomas D, Champlin RE, Kantarjian H. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013;13(3):296–301. Scholar
  125. 125.
    Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Brummendorf TH. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119(15):3403–12. Scholar
  126. 126.
    Kieslich M, Porto L, Lanfermann H, Jacobi G, Schwabe D, Bohles H. Cerebrovascular complications of l-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003;25(6):484–7.CrossRefGoogle Scholar
  127. 127.
    Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodriguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(22):2490–8. Scholar
  128. 128.
    Kite Pharma Inc. Yescarta (axicabtagene ciloleucel) [package insert]. Santa Monica; 2017.Google Scholar
  129. 129.
    Krause AS, Weihrauch MR, Bode U, Fleischhack G, Elter T, Heuer T, Engert A, Diehl V, Josting A. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphoma. 2002;43(11):2139–43. Scholar
  130. 130.
    Kuhlen M, Bleckmann K, Moricke A, Schrappe M, Vieth S, Escherich G, Bronsema A, Vonalt A, Queudeville M, Zwaan CM, Ebinger M, Debatin KM, Klingebiel T, Koscielniak E, Rossig C, Burkhardt B, Kolb R, Eckert C, Borkhardt A, von Stackelberg A, Chen-Santel C. Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy. Br J Haematol. 2017;179(2):272–83. Scholar
  131. 131.
    Lambertini M, Del Mastro L, Gardin G, Levaggi A, Bighin C, Giraudi S, Pronzato P. Stevens-Johnson syndrome after treatment with bendamustine. Leuk Res. 2012;36(7):e153–4. Scholar
  132. 132.
    Lancet JE, Uy G, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Chiarella M, Louie AC, Medeiros BC (Abstract 7000) Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. J Clin Oncol. 2016; 34(15 Suppl): p. 7000.Google Scholar
  133. 133.
    Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. Scholar
  134. 134.
    Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol. 2013;31(2):103–9. Scholar
  135. 135.
    Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S, Dorken B, Valent P. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011;103(17):1347–8. Scholar
  136. 136.
    Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist. 2013;18(8):900–8. Scholar
  137. 137.
    Lilly USA LLC. Verzenio (abemaciclib) [package insert]. Indianapolis; 2017.Google Scholar
  138. 138.
    Linette DC, McGee KH, McFarland JA. Mitomycin-induced pulmonary toxicity: case report and review of the literature. Ann Pharmacother. 1992;26(4):481–4. Scholar
  139. 139.
    Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(5):612–21. Scholar
  140. 140.
    Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–6. Scholar
  141. 141.
    Malalagama GN, Chryssidis S, Parnis FX. CT findings in patients with Cabazitaxel induced pelvic pain and haematuria: a case series. Cancer Imaging. 2017;17(1):17. Scholar
  142. 142.
    Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17(4):1141. Scholar
  143. 143.
    Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA. Tisagenlecleucel in children and young adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439–48. Scholar
  144. 144.
    Mayne Pharma Limited. Epirubicin hydrochloride [package insert]. Paramus; 2006.Google Scholar
  145. 145.
    McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, Kuzel TM, Trifilio SM, Raisch DW, Kell J, DeAngelo DJ, Giles FJ. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31(5):599–604. Scholar
  146. 146.
    McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829–30. Scholar
  147. 147.
    Merck & Co. Temodar (temozolomide) [package insert]. Whitehouse Station; 2017a.Google Scholar
  148. 148.
    Merck & Co. Keytruda (pembrolizumab) [package insert]. Whitehouse Station; 2017b.Google Scholar
  149. 149.
    Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy. 1997;17(4):729–36.PubMedGoogle Scholar
  150. 150.
    Millennium Pharmaceuticals Inc. Velcade (bortezomib) [package insert]. Cambridge, MA; 2017.Google Scholar
  151. 151.
    Mitani S, Kadowaki S, Komori A, Sugiyama K, Narita Y, Taniguchi H, Ura T, Ando M, Sato Y, Yamaura H, Inaba Y, Ishihara M, Tanaka T, Tajika M, Muro K. Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: a case series and review of the literature. Medicine. 2017;96(22):e6874. Scholar
  152. 152.
    Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O’Callaghan DS, Jais X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–37. Scholar
  153. 153.
    Montesinos P, Bergua JM, Vellenga E, Rayon C, Parody R, de la Serna J, Leon A, Esteve J, Milone G, Deben G, Rivas C, Gonzalez M, Tormo M, Diaz-Mediavilla J, Gonzalez JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775–83. Scholar
  154. 154.
    Moskovitz M, Wollner M, Haim N. Oxaliplatin-induced pulmonary toxicity in gastrointestinal malignancies: two case reports and review of the literature. Case Rep Oncol Med. 2015;2015:341064. Scholar
  155. 155.
    Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol. 2015;33(35):4210–8. Scholar
  156. 156.
    Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012;30(12):1371–7. Scholar
  157. 157.
    Munch M, Peuvrel L, Brocard A, Saint Jean M, Khammari A, Dreno B, Quereux G. Early-onset vemurafenib-induced DRESS syndrome. Dermatology (Basel, Switzerland). 2016;232(1):126–8. Scholar
  158. 158.
    Myint ZW, Sen JM, Watts NL, Druzgal TJ, Nathan BR, Ward MD, Boyer JE, Fracasso PM. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors. Clin Colorectal Cancer. 2014;13(2):127–30. Scholar
  159. 159.
    Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375–91. Scholar
  160. 160.
    Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709–17. Scholar
  161. 161.
    Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–44. Scholar
  162. 162.
    Nesher L, Rolston KV. Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis. 2013;56(5):711–7. Scholar
  163. 163.
    NIH NCI. A to Z list of cancer drugs; 2018. Viewed 20 March 2018.
  164. 164.
    Novartis Pharmaceutical Co. Afinitor and Afinitor Disperz (everolimus) [package insert]. East Hanover; 2017a.Google Scholar
  165. 165.
    Novartis Pharmaceutical Co. Tykerb (Lapatinib) [package insert]. East Hanover; 2017b.Google Scholar
  166. 166.
    Novartis Pharmaceutical Co. Votrient (pazopanib) [package insert]. East Hanover; 2017c.Google Scholar
  167. 167.
    Novartis Pharmaceutical Co. Zykadia (ceritinib) [package insert] East Hanover; 2017d.Google Scholar
  168. 168.
    Novartis Pharmaceuticals. Hycamtin (topotecan oral capsules) [package insert]. East Hanover; 2016.Google Scholar
  169. 169.
    Novartis Pharmaceuticals. Kasqali (ribociclib) [package insert]. East Hanover; 2017a.Google Scholar
  170. 170.
    Novartis Pharmaceuticals. Mekinist (trametinib) [package insert]. East Hanover; 2017b.Google Scholar
  171. 171.
    Novartis Pharmaceuticals. Tafinlar (dabrafenib) [package insert]. East Hanover; 2017c.Google Scholar
  172. 172.
    Novartis Pharmaceuticals. Tasigna oral capsules, nilotinib oral capsules [package insert]. East Hanover; 2018.Google Scholar
  173. 173.
    Novartis Pharmaceuticals Corporation. Farydak (panobinostat) [package insert]. East Hanover; 2016.Google Scholar
  174. 174.
    Novartis Pharmaceuticals Corporation. Kymriah (tisagenlecleucel) [prescribing information]. East Hanover; 2017.Google Scholar
  175. 175.
    Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia. 2006;20(6):1162–4. Scholar
  176. 176.
    Okamoto K, Proia LA, Demarais PL. Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib. Case Rep Infect Dis. 2016;2016:4642831. Scholar
  177. 177.
    Okuno SH, Frytak S. Mitomycin lung toxicity. Acute and chronic phases. Am J Clin Oncol. 1997;20(3):282–4.CrossRefGoogle Scholar
  178. 178.
    Onyx Pharmaceuticals Inc. Kyprolis (carfilzomib) [package insert]. Thousand Oaks; 2018.Google Scholar
  179. 179.
    Osawa M, Kudoh S, Sakai F, Endo M, Hamaguchi T, Ogino Y, Yoneoka M, Sakaguchi M, Nishimoto H, Gemma A. Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study. Int J Clin Oncol. 2015;20(6):1063–71. Scholar
  180. 180.
    OSI Pharmaceuticals L, an affiliate of Astellas Pharma US, Inc. Tarceva (erlotinib) [package insert]. Northbrook; 2016.Google Scholar
  181. 181.
    Otsuka America Pharmaceutical. Busulfan [package insert]. Rockville; 2015.Google Scholar
  182. 182.
    Ovation Pharmaceuticals. Cosmegen (dactinomycin) [package insert]. Deerfield; 2008.Google Scholar
  183. 183.
    Patel PN. Methylene blue for management of Ifosfamide-induced encephalopathy. Ann Pharmacother. 2006;40(2):299–303. Scholar
  184. 184.
    Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83(6):679–86. Scholar
  185. 185.
    Peroukides S, Makatsoris T, Koutras A, Tsamandas A, Onyenadum A, Labropoulou-Karatza C, Kalofonos H. Lapatinib-induced hepatitis: a case report. World J Gastroenterol. 2011;17(18):2349–52. Scholar
  186. 186.
    Petri CR, O'Donnell PH, Cao H, Artz AS, Stock W, Wickrema A, Hard M, van Besien K. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014;55(12):2866–73. Scholar
  187. 187.
    Pfizer. Inlyta (axitinib) [package insert]. New York; 2014.Google Scholar
  188. 188.
    Pfizer. Navelbine (vinorelbine) [package insert]; Research Triangle Park; 2017a.Google Scholar
  189. 189.
    Pfizer. Sutent (sunitinib) [package insert]. New York; 2017b.Google Scholar
  190. 190.
    Pfizer Inc. Xalkori (crizotinib) [package insert]. New York; 2017.Google Scholar
  191. 191.
    Pfizer Labs. Ibrance (palbociclib) [package insert]. New York; 2017.Google Scholar
  192. 192.
    Pharmacia & Upjohn Camptosar (irinotecan) [package insert]. New York; 2016.Google Scholar
  193. 193.
    Pharmacyclics. Imbruvica (ibrutinib) [package insert]. Sunnyvale; 2017.Google Scholar
  194. 194.
    Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116(2):377–86. Scholar
  195. 195.
    Prasco Laboratories. Leukeran (chlorambucil) [package insert]. Mason; 2017.Google Scholar
  196. 196.
    Prometheus Laboratories Inc. Proleukin (aldesleukin) [prescribing information]. San Diego; 2012.Google Scholar
  197. 197.
    Qi WX, Fu S, Zhang Q, Guo XM. Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups. Clin Drug Investig. 2014;34(10):681–90. Scholar
  198. 198.
    Quintas-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12(5):337–40. Scholar
  199. 199.
    Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer. 2002;94(3):847–53.CrossRefGoogle Scholar
  200. 200.
    Robertson GL, Bhoopalam N, Zelkowitz LJ. Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med. 1973;132(5):717–20.CrossRefGoogle Scholar
  201. 201.
    Roboz GJ, Ritchie EK, Carlin RF, Samuel M, Gale L, Provenzano-Gober JL, Curcio TJ, Feldman EJ, Kligfield PD. Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. J Clin Oncol. 2014;32(33):3723–8. Scholar
  202. 202.
    Rosen AC, Balagula Y, Raisch DW, Garg V, Nardone B, Larsen N, Sorrell J, West DP, Anadkat MJ, Lacouture ME. Life-threatening dermatologic adverse events in oncology. Anti-Cancer Drugs. 2014;25(2):225–34. Scholar
  203. 203.
    Rothenstein JM, Letarte N. Managing treatment-related adverse events associated with Alk inhibitors. Curr Oncol (Toronto, Ont). 2014;21(1):19–26. Scholar
  204. 204.
    Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G, Terris B. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460–6.CrossRefGoogle Scholar
  205. 205.
    Sager PT, Balser B, Wolfson J, Nichols J, Pilot R, Jones S, Burris HA. Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin. Cancer Med. 2015;4(8):1178–85. Scholar
  206. 206.
    Saif MW, McGee PJ. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. J Pancreas. 2005;6(4):369–74.Google Scholar
  207. 207.
    Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: recognition and management. J Support Oncol. 2008;6(1):41–8.PubMedGoogle Scholar
  208. 208.
    Salloum E, Khan KK, Cooper DL. Chlorambucil-induced seizures. Cancer. 1997;79(5):1009–13.CrossRefGoogle Scholar
  209. 209.
    Sankhalla KK, Chawla NS, Syed I, Chawla SP. Management of toxicities with pazopanib in advanced soft tissue sarcoma. Sarcoma Res Int. 2016;3(2):1032–8.Google Scholar
  210. 210.
    Sanofi-Aventis. Zaltrapt (afilibercept) [package insert]. Bridgewater; 2016.Google Scholar
  211. 211.
    Sanofi-Aventis LLC. Eloxatin (oxaliplatin) [package insert]. Bridgewater; 2015.Google Scholar
  212. 212.
    Sanofi-Aventis U.S. LLC. Taxotere (docetaxel) [package insert]. Bridgewater; 2015.Google Scholar
  213. 213.
    Sanofi-Aventis U.S. LLC. Jevtana (cabazitaxel) [package insert]. Bridgewater; 2017.Google Scholar
  214. 214.
    Sanofi Genzyme Corp. Caprelsa (vandetanib) [package insert]. Cambridge, MA; 2016.Google Scholar
  215. 215.
    Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood. 2014;123(18):2777–82. Scholar
  216. 216.
    Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–12. Scholar
  217. 217.
    Seattle Genetics. Adcetris (brentuximab vedotin) [package insert]. Bothell; 2017.Google Scholar
  218. 218.
    Seet RC, Rabinstein AA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM. 2012;105(1):69–75. Scholar
  219. 219.
    Serota DP, Mehta AK, Phadke VK. Invasive fungal sinusitis due to Mucor species in a patient on ibrutinib. Clin Infect Dis. 2017;
  220. 220.
    Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19):3204–12. Scholar
  221. 221.
    Shank BR, Do B, Sevin A, Chen SE, Neelapu SS, Horowitz SB. Chimeric Antigen Receptor T Cells in Hematologic Malignancies. Pharmacotherapy. 2017;37(3):334–45. Scholar
  222. 222.
    Sharief U, Perry DJ. Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin. Clin Colorectal Cancer. 2009;8(3):163–5. Scholar
  223. 223.
    Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–94. Scholar
  224. 224.
    Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–54. Scholar
  225. 225.
    Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–84. Scholar
  226. 226.
    Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol. 1997;15(2):833–9. Scholar
  227. 227.
    Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet (London, England). 2017;389(10072):917–29. Scholar
  228. 228.
    Spectrum Pharmaceuticals Beleodaq (belinostat) [package insert]. Irvine; 2017.Google Scholar
  229. 229.
    Steeghs N, de Jongh FE, Sillevis Smitt PA, van den Bent MJ. Cisplatin-induced encephalopathy and seizures. Anti-Cancer Drugs. 2003;14(6):443–6. Scholar
  230. 230.
    Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–31. Scholar
  231. 231.
    Stoica GS, Greenberg HE, Rossoff LJ. Corticosteroid responsive fludarabine pulmonary toxicity. Am J Clin Oncol. 2002;25(4):340–1.CrossRefGoogle Scholar
  232. 232.
    Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105(1):54–60. Scholar
  233. 233.
    Sun Pharmaceutical Industries. Odomzo (sonidegib) [package insert]. Cranbury; 2017.Google Scholar
  234. 234.
    SuperGen. Mitozytrex (mitomycin) [package insert]. Dublin; 2002.Google Scholar
  235. 235.
    Swain SM, Ewer MS, Cortes J, Amadori D, Miles D, Knott A, Clark E, Benyunes MC, Ross G, Baselga J. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist. 2013;18(3):257–64. Scholar
  236. 236.
    Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2002;47(5):672–84.CrossRefGoogle Scholar
  237. 237.
    Tesaro Inc. Zejula (niraparib) [package insert]. Waltham; 2017.Google Scholar
  238. 238.
    Teva Pharmaceuticals Inc. Adrucil (fluorouracil injection) [package insert]. North Wales; 2017.Google Scholar
  239. 239.
    Teva Pharmaceuticals USA Inc. Bendeka (bendamustine hydrochloride) [package insert]. North Wales; 2017.Google Scholar
  240. 240.
    Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Balint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):763–74. Scholar
  241. 241.
    Thornburg A, Abonour R, Smith P, Knox K, Twigg HL 3rd. Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. Chest. 2007;131(5):1572–4. Scholar
  242. 242.
    Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, Neumann SA, Horst HA, Raff T, Viardot A, Stelljes M, Schaich M, Kohne-Volland R, Bruggemann M, Ottmann OG, Burmeister T, Baeuerle PA, Nagorsen D, Schmidt M, Einsele H, Riethmuller G, Kneba M, Hoelzer D, Kufer P, Bargou RC. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage all. Blood. 2012;120(26):5185–7. Scholar
  243. 243.
    Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, Viardot A, Marks R, Diedrich H, Faul C, Reichle A, Horst HA, Bruggemann M, Wessiepe D, Holland C, Alekar S, Mergen N, Einsele H, Hoelzer D, Bargou RC. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134–40. Scholar
  244. 244.
    Umemura S, Yamane H, Suwaki T, Katoh T, Yano T, Shiote Y, Takigawa N, Kiura K, Kamei H. Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer. J Cancer Res Clin Oncol. 2011;137(10):1469–75. Scholar
  245. 245.
    United Therapeutics Corp. Unituxin (dinutuximab) [package insert]. Silver Spring; 2015.Google Scholar
  246. 246.
    Vahid B, Marik PE. Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies. Can Respir J. 2008;15(4):211–6.CrossRefGoogle Scholar
  247. 247.
    Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood. 2015;125(6):901–6. Scholar
  248. 248.
    Verweij J, van Zanten T, Souren T, Golding R, Pinedo HM. Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer. 1987;60(4):756–61.CrossRefGoogle Scholar
  249. 249.
    Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102(5):1578–82. Scholar
  250. 250.
    Wanchoo R, Abudayyeh A, Doshi M, Edeani A, Glezerman IG, Monga D, Rosner M, Jhaveri KD. Renal toxicities of novel agents used for treatment of multiple myeloma. Clin J Am Soc Nephrol. 2017;12(1):176–89. Scholar
  251. 251.
    Wanchoo R, Jhaveri KD, Deray G, Launay-Vacher V. Renal effects of BRAF inhibitors: a systematic review by the cancer and the Kidney International Network. Clin Kidney J. 2016;9(2):245–51. Scholar
  252. 252.
    Waters MJ, Sukumaran S, Karapetis CS. Pemetrexed-Induced Interstitial pneumonitis: a case study and literature review. World J Oncol. 2014;5(5–6):232–6. Scholar
  253. 253.
    Weiss RB, Poster DS, Penta JS. The nitrosoureas and pulmonary toxicity. Cancer Treat Rev. 1981;8(2):111–25.CrossRefGoogle Scholar
  254. 254.
    Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–41. Scholar
  255. 255.
    Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015;7(2):122–36. Scholar
  256. 256.
    Wenk KS, Pichard DC, Nasabzadeh T, Jang S, Venna SS. Vemurafenib-induced DRESS. JAMA Dermatol. 2013;149(10):1242–3. Scholar
  257. 257.
    West-ward Pharmaceuticals. Thiotepa [package insert]. Eatontown; 2015.Google Scholar
  258. 258.
    Zamorano JL, Lancellotti P, Munoz DR, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Fernandez TL, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines. Kardiol Pol. 2016;74(11):1193–233. Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Melvin J. Rivera
    • 1
  • Bryan Do
    • 2
  • Jeffrey C. Bryan
    • 3
  • Terri Lynn Shigle
    • 4
    • 5
  • Rina Patel
    • 6
    Email author
  1. 1.Thoracic / Head and Neck MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Lymphoma and MyelomaThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.LeukemiaThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  5. 5.Stem Cell Transplantation and Cellular TherapyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  6. 6.Critical Care / Nutrition SupportThe University of Texas MD Anderson Cancer CenterHoustonUSA

Section editors and affiliations

  • Todd W. Canada
    • 1
  • Jeffrey J. Bruno
    • 2
  1. 1.Clinical Pharmacy Svcs, Pharmacy Clinical ProgramsThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Clinical Pharmacy Specialist – Critical Care / Nutrition SupportThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations